Glaukos Corporation $GKOS Stock: Allspring Global Investments Holdings LLC Reduces Stake

Allspring Global Investments Holdings LLC reduced its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 16.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 347,235 shares of the medical instruments supplier’s stock after selling 70,764 shares during the period. Allspring Global Investments Holdings LLC owned 0.59% of Glaukos worth $56,658,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in GKOS. Allworth Financial LP acquired a new stake in Glaukos in the second quarter worth approximately $28,000. CoreCap Advisors LLC bought a new stake in shares of Glaukos in the 3rd quarter worth $33,000. Fortitude Family Office LLC bought a new stake in shares of Glaukos in the 3rd quarter worth $36,000. Parallel Advisors LLC raised its stake in shares of Glaukos by 159.2% in the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Glaukos by 523.4% in the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 246 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total value of $632,500.00. Following the sale, the director owned 37,406 shares of the company’s stock, valued at $9,463,718. The trade was a 6.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. Wall Street Zen upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a report on Saturday. Piper Sandler reissued an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a research report on Thursday, October 29th. Citigroup increased their price objective on Glaukos from $225.00 to $247.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Finally, BTIG Research increased their price objective on Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $216.71.

Read Our Latest Analysis on GKOS

Glaukos Trading Down 0.8%

GKOS opened at $236.81 on Wednesday. The company has a current ratio of 4.57, a quick ratio of 4.09 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $180.57 and a 200-day moving average of $145.22. Glaukos Corporation has a 52-week low of $87.32 and a 52-week high of $255.18.

Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The firm’s revenue for the quarter was up 58.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) earnings per share. Equities analysts forecast that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.

Glaukos Profile

(Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Read More

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.